Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

New Phase I data for ASN002 shows promise

ASN002 is the first oral Janus kinase (JAK)-spleen tyrosine kinase (SYK) inhibitor to demonstrate correlations between improvements in clinical outcomes and molecular changes in the skin and serum of atopic dermatitis patients. Credit: Courtesy of Assianir

  • ASN002

Go Top